Shopping Cart
Remove All
Your shopping cart is currently empty
Faricimab
😃Good
Catalog No. T78253Cas No. 1607793-29-2
Alias RG-7716, RG7716
Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.
Faricimab
Faricimab
😃Good
Catalog No. T78253Alias RG-7716, RG7716Cas No. 1607793-29-2
Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $645 | - | In Stock | |
| 5 mg | $1,690 | - | In Stock | |
| 10 mg | $2,680 | 2-4 weeks | 2-4 weeks | |
| 25 mg | $3,990 | 2-4 weeks | 2-4 weeks |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:>95% (SDS-PAGE); >95% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO. |
| In vivo | Faricimab (10 mg/kg, intraperitoneal injection, once a week, 1-5 weeks) can reduce spontaneous choroidal neovascularization (sCNV), lesion leakage area and subretinal Iba1+, CD11b+, CD45+ cell infiltration in JR5558 mice. [1] |
| Synonyms | RG-7716, RG7716 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | ANG2 & VEGFA |
| Molecular Weight | 146 kDa |
| Cas No. | 1607793-29-2 |
| Isotype | Human IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Faricimab | purchase Faricimab | Faricimab cost | order Faricimab | Faricimab in vivo | Faricimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.